Trials / Active Not Recruiting
Active Not RecruitingNCT03787680
Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)
A Multi-Center Phase II Study Testing the Activity of Olaparib and AZD6738 (ATR Inhibitor) in Metastatic Castration-Resistant Prostate Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 49 (actual)
- Sponsor
- University of Michigan Rogel Cancer Center · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the effectiveness (how well the drugs work), safety, and tolerability of the investigational drug combination of olaparib and AZD6738 for all patients with metastatic castration-resistant prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Olaparib | 300 mg by mouth twice a day for days 1-28 of a 28-day cycle. |
| DRUG | AZD6738 | 160 mg by mouth daily for days 1-7 of a 28-day cycle. |
Timeline
- Start date
- 2019-10-31
- Primary completion
- 2023-01-26
- Completion
- 2028-08-01
- First posted
- 2018-12-26
- Last updated
- 2026-03-23
- Results posted
- 2024-08-12
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03787680. Inclusion in this directory is not an endorsement.